Forty-seven LEAD Coalition member organizations and supporters joined together to submit formal comment welcoming the U.S. Food and Drug Administration (FDA) draft guidance which outlines FDA’s current thinking as to how to a drug developer may demonstrate efficacy in clinical trials in patients in the early stages of Alzheimer’s disease that occur before the onset of overt dementia.
LEAD Coalition Comments on FDA Draft Guidance for Development of Drugs for Early Stage Alzheimer’s Disease
